TAF with a boosted protease inhibitor — Competitive Intelligence Brief

TAF with a boosted protease inhibitor (TAF with a boosted protease inhibitor) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) HIV reverse transcriptase and HIV protease Infectious Disease / Virology Small molecule

Target snapshot

TAF with a boosted protease inhibitor (TAF with a boosted protease inhibitor) — University of Colorado, Denver. TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that, when combined with a boosted protease inhibitor, blocks HIV replication by inhibiting both reverse transcriptase and protease enzymes.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAF with a boosted protease inhibitor TARGET	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease
zidovudine+lamivudine+lopinavir/ritonavir	zidovudine+lamivudine+lopinavir/ritonavir	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase and HIV protease
Combivir+Kaletra	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) class)

1. University of Colorado, Denver · 1 drug in this class